Sweden's SynAct Pharma Q4 net loss widens as expenses rise

SynAct Pharma AB

18/02/2026 06:37

Overview

Sweden-based biotech firm's Q4 net sales were zero, consistent with clinical focus

Operating expenses rose 9% in Q4, contributing to a net loss of SEK 22.9 mln

Company initiated Phase 2 study in respiratory insufficiency post-Q4

Outlook

SynAct Pharma did not provide specific financial guidance for 2026

Result Drivers

CLINICAL DEVELOPMENT - SynAct Pharma focused on advancing resomelagon (AP1189) for inflammatory diseases, with 190 patients randomized in Phase 2b study

MANAGEMENT CONFIDENCE - Management and Chairman acquired shares and entered lock-up agreements, indicating confidence in the company's future

PHASE 2 STUDY INITIATION - Post-Q4, SynAct initiated a Phase 2 study in respiratory insufficiency

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 0
Q4 Adjusted EPS
-SEK 0.43
Q4 Net Income
-SEK 22.93 mln
Q4 Cash Flow From Operating Activities
-SEK 23.97 mln
Q4 Operating Expenses
SEK 22.72 mln


Analyst Coverage

Wall Street's median 12-month price target for SynAct Pharma AB is SEK26.00, about 45.9% above its February 17 closing price of SEK17.82

Press Release: ID:nMFN8rR9s7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)